Stock Price Forecast The 4 analysts offering 12-month price forecasts for Vyne Therapeutics Inc have a median target of 6.00, with a high estimate of 10.00 and a low estimate of 3.00. The median estimate represents a +864.17% increase from the last price of 0.62.
Who bought VYNE stock?
Stockholder Stake Shares bought / sold
---------------------------- ----- --------------------
Franklin Advisers, Inc. 3.59% +20,373
Renaissance Technologies LLC 2.33% +934,100
DSC Advisors LP 2.06% 0
BlackRock Fund Advisors 1.87% -4,096
Is VNUE a good stock to buy?
If you are looking for stocks with good return, VNUE Inc can be a profitable investment option. VNUE Inc quote is equal to 0.01020 USD at 2022-01-31. Based on our forecasts, a long-term increase is expected, the "VNUE" stock price prognosis for 2027-01-22 is 0.741 USD.
Is VYNE stock a good buy?
VYNE Therapeutics has received a consensus rating of Buy.
Is VYNE undervalued?
Is VYNE Therapeutics Inc Stock Undervalued? The Score for VYNE is 15, which is 70% below its historic median score of 50, and infers higher risk than normal. VYNE is currently trading in the 10-20% percentile range relative to its historical Stock Score levels.
Does BlackRock own VYNE?
OWNER NAME
----------
09/30/2021
1,037,271
-406
-0.039%
Should you buy VYNE stock?
There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VYNE Therapeutics stock.